These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2412045)

  • 1. Effect of ketanserin in primary aldosteronism.
    Mantero F; Rocco S; Opocher G; Armanini D; Boscaro M; D'Agostino D
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S172-5. PubMed ID: 2412045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension.
    Rossi GP; Ganzaroli C; Cesari M; Maresca A; Plebani M; Nussdorfer GG; Pessina AC
    Cardiovasc Res; 2003 Jan; 57(1):277-83. PubMed ID: 12504838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of trilostane, a new inhibitor of adrenal steroid biosynthesis, on blood pressure, plasma aldosterone and other steroid hormones, serum potassium and plasma renin activity in primary aldosteronism (author's transl)].
    Shigetomi S; Fukuchi S; Haruyama K; Yamazaki M
    Nihon Naibunpi Gakkai Zasshi; 1982 Mar; 58(3):184-98. PubMed ID: 6212269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism.
    Gross MD; Grekin RJ; Gniadek TC; Villareal JZ
    N Engl J Med; 1981 Jul; 305(4):181-5. PubMed ID: 7017408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ketanserin, a new inhibitor of 5-HT2 receptors, on plasma renin activity and aldosterone levels in normal subject.
    Degli Uberti EC; Trasforini G; Margutti AR; Rotola CA; Pansini R
    Horm Res; 1982; 16(4):244-8. PubMed ID: 6751979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of aldosterone secretion in primary aldosteronism.
    Vetter H; Vetter W
    Horm Metab Res; 1975 Sep; 7(5):418-24. PubMed ID: 1183923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
    Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case.
    Sundsfjord JA; Marton P; Jorgensen H; Aakvaag A
    J Clin Endocrinol Metab; 1974 Oct; 39(4):734-9. PubMed ID: 4370321
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new diagnostic test for primary aldosteronism.
    Coruzzi P; Musiari L; Biggi A; Carra N; Panzali AF; Novarini A
    Am J Hypertens; 1991 Aug; 4(8):694-9. PubMed ID: 1930852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma aldosterone in idiopathic aldosteronism.
    Veglio F; Pinna G; Bisbocci D; Rabbia F; Piras D; Chiandussi L
    J Hum Hypertens; 1990 Oct; 4(5):579-82. PubMed ID: 2283648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism.
    Schambelan M; Brust NL; Chang BC; Slater KL; Biglieri EG
    J Clin Endocrinol Metab; 1976 Jul; 43(1):115-31. PubMed ID: 947931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the serotonin 5-HT4 receptor agonist cisapride on aldosterone secretion in corticotropic insufficiency and primary hyperaldosteronism.
    Lefebvre H; Dhib M; Godin M; Contesse V; Delarue C; Rieu M; Wolf LM; Vaudry H; Kuhn JM
    Neuroendocrinology; 1997 Sep; 66(3):229-33. PubMed ID: 9380281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone and blood pressure relationships in primary aldosteronism.
    Nicholls MG; Espiner EA; Ikram H; Maslowski AH; Hamilton EJ; Bones PJ
    Clin Exp Hypertens A; 1984; 6(8):1441-58. PubMed ID: 6388912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.
    Stimpel M; Ivens K; Volkmann HP; Wambach G; Kaufmann W
    Klin Wochenschr; 1989 Feb; 67(4):248-52. PubMed ID: 2648061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarity of idiopathic aldosteronism and essential hypertension. A statistical comparison.
    McAreavey D; Murray GD; Lever AF; Robertson JI
    Hypertension; 1983; 5(1):116-21. PubMed ID: 6336718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ketanserin, an inhibitor of 5-HT2 receptors, on the aldosterone-stimulating action of metoclopramide.
    Degli Uberti EC; Trasforini G; Margutti AR; Rotola CA; Bianconi M; Pansini P
    Horm Res; 1983; 17(3):160-7. PubMed ID: 6343215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism.
    Kem DC; Weinberger MH; Gomez-Sanchez C; Kramer NJ; Lerman R; Furuyama S; Nugent CA
    J Clin Invest; 1973 Sep; 52(9):2272-7. PubMed ID: 4353776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.